Industry groups have identified upfront costs as a barrier to streamlining U.S. drugmaking. The nonprofit API Innovation Center has a proposed answer for how to tilt finances in favor of investments ...

Lilly’s Japan outlay comes on the heels of a major $3 billion investment in the company’s manufacturing operations in China, where the pharma giant has pledged to set up local production for oral ...

The API Innovation Center (APIIC), a nonprofit dedicated to strengthening national health security through U.S. generic pharmaceutical manufacturing and public-private collaboration, today released ...

ESTEVE CDMO, a global CDMO specializing in high-quality small-molecule APIs and pharmaceutical intermediates, began a $15.5 ...

While solely API-focused players currently face increased competition, this transition is expected to strengthen long-term pricing power, improve margins, enhance compliance, and increase customer ...

With a substantial manufacturing base already locked down in China, CRDMO BioDuro is taking a short jaunt down to Taiwan for its latest drug ingredients production play.  | BioDuro, headquartered in ...

Construction is scheduled to commence in spring 2026, with both facilities anticipated to be fully operational by 2029.

BofA Securities 2026 Information & Business Services Conference March 12, 2026 2:15 PM EDTCompany ParticipantsAdam ...

As the pharmaceutical industry continues to evolve in the wake of pandemic-driven disruptions and heightened regulatory scrutiny, the role of the top pharmaceutical API manufacturer has taken on ...

BioDuro, a CRDMO, has established a joint venture with Cenra API Solutions, a pharmaceutical chemical manufacturer in Taiwan.

However, achieving the manufacturing prowess alone is not enough. The other aspect now involves the efficient transportation ...

The Contract Development and Manufacturing Organization (CDMO) industry in India is a fast-growing segment of the pharmaceutical sector that provides outsourced drug development and manufacturing ...